Definitive Healthcare Corp. Class A (DH)

The past six months have seen several events impacting Definitive Healthcare Corp.'s (DH) stock price, which has experienced a significant decline. In the Q4 2025 earnings report, Definitive Healthcare reported revenue of $61.5 million, down 1% year-over-year, and an EPS of -$0.09, missing the forecasted $0.06. In the Q3 2025 earnings report, the company reported revenue of $60.0 million, down 4% year-over-year, and a net loss of $(17.8) million. Several analysts reduced their price targets for Definitive Healthcare's stock. Total customers declined to 2,330 in Q4 2025 from 2,400 in Q3 2025, and enterprise customers fell to 511 from 520 in the same period. Jeff Haywood resigned from the Board of Directors and the Human Capital Management and Compensation Committee.

There is no explicit indication of strong demand seasonality for Definitive Healthcare Corp.'s products and services themselves. The company operates on a SaaS subscription model, which typically aims for recurring revenue. Definitive Healthcare's products are designed to help its clients understand and predict market trends and patient demand within the broader healthcare sector. The company's focus on providing continuous commercial intelligence for strategic decision-making across various functional areas further supports the idea of a relatively stable demand for its data and analytics services.

Definitive Healthcare Corp. (DH) is a leading provider of healthcare commercial intelligence, operating a SaaS platform that offers comprehensive information on the U.S. healthcare ecosystem. The company's mission is to provide trusted intelligence on healthcare organizations, clinicians, claims, consumers, and experts to help customers make data-driven strategic decisions. The company operates within the Healthcare sector, specifically in the Health Information Services and Health Care Technology industries, and is categorized under Business/Productivity Software and Research and Development in the Physical, Engineering, and Life Sciences. Definitive Healthcare's major products and solutions include the View Suite, Monocl Expert Suite, Populi Suite, Carevoyance, Market Forecast, Digital Audiences and Population Intelligence, and Market Intelligence. The company serves a diverse customer base, including biopharmaceutical and medical device companies, healthcare information technology companies, healthcare providers, and other diversified companies.

Definitive Healthcare is a global organization with offices in the U.S., Sweden, and India. The company primarily focuses on the U.S. healthcare ecosystem and derives a majority of its revenue from the United States. Its SaaS platform is designed to provide comprehensive information on the healthcare ecosystem in the U.S.

Definitive Healthcare's brand reputation presents a mixed picture. The company is recognized as a leader in healthcare commercial intelligence, with its platform being utilized by approximately 2,500 customers. Customer reviews on G2 give Definitive Healthcare an average rating of 3.9 out of 5 stars, and MarketBeat reported a generally positive news coverage. However, the company has faced challenges that could impact its reputation, including negative stock performance, analyst downgrades, and some negative customer feedback. The decline in total and enterprise customer counts in Q4 2025 also suggests some challenges in customer acquisition and retention.

Definitive Healthcare Corp. (DH) has a concentrated ownership structure, with institutional investors holding a significant majority of shares. Major institutional owners include Advent International Corp/ma, Goldman Sachs Group Inc, and BlackRock, Inc. Key individual owners include founder Jason Krantz and David Mussafer.